Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Additional drug combinations may carry a risk of more side effects though, raising concerns from some doctors. Regeneron ...

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, ...